The International Trade Commission published notices in the Nov. 24 Federal Register on the following antidumping and countervailing duty injury, Section 337 patent or other trade proceedings (any notices that warrant a more detailed summary will be in another ITT article):
The Commerce Department published notices in the Federal Register Nov. 19 on the following antidumping and countervailing duty (AD/CVD) proceedings (any notices that announce changes to AD/CVD rates, scope, affected firms or effective dates will be detailed in another ITT article):
A domestic producer recently filed a petition with the Commerce Department and the International Trade Commission requesting antidumping and countervailing duties be imposed on van-type trailers and subassemblies from Canada, Mexico and China. Commerce now will decide whether to begin AD/CVD investigations, which could result in the imposition of permanent AD/CVD orders and the assessment of AD and CVD on importers. The investigation was requested by the American Trailer Manufacturers Coalition, which consists of Great Dane, Stoughton Trailers and Wabash National Corp.
The International Trade Commission published notices in the Nov. 21 Federal Register on the following antidumping and countervailing duty injury, Section 337 patent or other trade proceedings (any notices that warrant a more detailed summary will be in another ITT article):
The Commerce Department has released the final results of the antidumping duty administrative review on acetone from South Korea (A-580-899). Commerce found the one company remaining under review, Kumho P&B Chemicals, Inc., did not undersell subject merchandise during the period of review, assigning it a zero percent AD rate. Subject merchandise from Kumho P&B Chemicals entered March 1, 2023, through Feb. 29, 2024, will be liquidated without any assessment of AD, and future entries of subject merchandise from the company won't be subject to AD cash deposit requirements until further notice. Cash deposit rates from these final results take effect Nov. 24, the date they are set to be published in the Federal Register.
The International Trade Commission published notices in the Nov. 20 Federal Register on the following antidumping and countervailing duty injury, Section 337 patent or other trade proceedings (any notices that warrant a more detailed summary will be in another ITT article):
The International Trade Commission seeks comments by Dec. 1 on a Section 337 complaint alleging that imports of smart rings infringe patents held by Ouraring, it said in a notice to be published Nov. 21 in the Federal Register. According to the complaint, Ouraring is seeking a limited exclusion order and cease and desist orders against Samsung, Reebok, their subsidiaries and seven other companies from the U.K., China, India and the U.S. to bar from entry "certain smart wearable devices, systems, and components thereof" that violate their patents. Ouraring said that its product is a smart ring that "accurately provides personalized insights into user’s fitness and health by monitoring heart rate, temperature variations, blood oxygen levels, and movement during both sleep and active periods."
The International Trade Commission seeks comments by Dec. 1 on a Section 337 complaint alleging that imports of microwave hoods infringe patents held by Whirlpool Corporation, it said in a notice to be published Nov. 21 in the Federal Register. According to the complaint, Whirlpool is seeking a limited exclusion order and cease and desist orders against Samsung and LG Electronics and their subsidiaries, and six U.S.- and Canada-based companies to bar from entry "certain low profile microwave-hood combination products" that violate their patents. Whirlpool said that its products "are designed to fit into the undercabinet hood space above a cooking range, providing a two-in-one kitchen appliance that cooks and provides ventilation."
The International Trade Commission seeks comments by Dec. 1 on a Section 337 complaint alleging that imports of antibody drugs infringe patents held by AbbVie Inc., and ImmunoGen, Inc., it said in a notice to be published Nov. 21 in the Federal Register. According to the complaint, AbbVie is seeking a limited exclusion order and cease and desist orders against ProfoundBio, Genmab and their subsidiaries to bar from entry "certain antibody drug conjugates products and components thereof and products containing the same" that violate their patents. AbbVie said that its product ELAHERE, is "a first-in-class ADC approved to treat adult patients with certain ovarian, fallopian tube, and primary peritoneal cancers."
The International Trade Commission published notices in the Nov. 19 Federal Register on the following antidumping and countervailing duty injury, Section 337 patent or other trade proceedings (any notices that warrant a more detailed summary will be in another ITT article):